We investigated the surface expression of leukocyte differentiation antigens and the Ig heavy-chain variable region (V, ) gene family use in leukemic cells from 26 Japanese patients with chronic B-cell leukemias with special reference to CD5 antigen expression. CD5 was expressed on leukemic cells in 21 of 26 cases (CD5') but not in 5 cases (CD5-I. Myelomonocytic marker, CD13 antigen was expressed on the leukemic cells in all 5 CD5-cases but in none of CD5' cases. Leukemic cells in CD5-cases also expressed C D l l b antigen more frequently than those in CD5' cases (80% v 11%; P < .01). Another myeloid marker, CD33, was expressed neither on CD5' nor CD5-leukemic cells. CD22, a restricted Btell marker, was expressed more frequently on CD5-leukemic cells than on CD5+ leukemic cells (80% ~3 3 % ; P < .051. Another restricted B-cell activation marker, CD23, was expressed at similar frequency in both the CD5+ and 0 5 -groups (67% ~6 0 % ) .
HRONIC B-CELL leukemias are known to be heterogeneous concerning morphology, immunophenotype, and clinical course.l-lo Phenotypic heterogeneity suggests that various B-lymphoid leukemic phenotypes might encompass a relatively broad spectrum of B-cell ontogeny and include minor subpopulations of B cells. CD5 expression is thought to be the marker of the distinct disease entity commonly referred to as chronic lymphocytic leukemia (CLL), as distinct from other chronic B-cell leukemia^.^.^." CD5+ B cells have attracted much attention concerning their function and ontogeny. Although CD5 antigen is expressed on the majority of B cells of early ontogeny, such as in the cord blood and fetal liver, it is expressed on only 20% of B cells in adult human peripheral CD5+ B cells are thought to be associated with some autoimmune disease^,'^,'^ and autoimmune phenomena have been recognized in some patients with B-CLL.2,1s, 16 Ig gene rearrangement is one of the characteristic features of B cells. Preferential heavy chain variable (V,) gene use is reported in early ontogeny of B cell^."^^^ In CD5+ BCLLs, developmentally restricted Ig genes that are often associated with anti-idiotype cross reactivitylg are preferen-on the majority of leukemic B cells, the CD45RA expression level was significantly higher among CD5-cases than CD5+ cases (P < .OIL In the analysis of V, gene expressed in chronic B-cell leukemias by polymerase chain reaction amplification. CD5' cases preferentially used V , 4 family members (48%; 10 of 21 1. CD5-cases, on the other hand, mainly used vH3 family (80%; 4 of 5). Thus, from our present observation of an albeit limited patient population, we have found an association between Vn gene family use and CD5 antigen expression in chronic &cell leukemias. We have also shown the differential expression of myelomonocytic markers in the CD5+ and CD5-chronic B-cell leukemias. These result are in agreement with previous suggestions that CD5 positivity is the hallmark for distinct clinical entity commonly referred to in the literature as chronic lymphocytic leukemia. 0 7994 by The American Society of Hematology.
tially utilized.20.z1 On the other hand, little is known about V, gene use by CD5-chronic leukemic B cells.
In the present study, we investigated the surface phenotypes and the VH gene family uses of CD5' and CD5-chronic B-cell leukemias to elucidate the differences between these two types of leukemic cells. We investigated the biphenotypic (lymphocytic and myelomonocytic) antigen expression, especially on CD5-leukemic B cells. This biphenotypic expression has already been observed in other B-cell malignancies, such as acute lymphocytic leuketo have important biologic and clinical implications. CD5-chronic leukemic B cells mainly used Ig v H 3 family members, whereas CD5+ leukemic B cells preferentially used V& members that are often used in B cells of the early ontogeny26 and in the autoantibody-producing B cells in patients with some autoimmune disease^.^^,^' mias22.23 and multiple myeloma^:^*^' and has been thought
MATERIALS AND METHODS
Patients and morphologic classijication. Twenty-six Japanese patients with chronic B-cell leukemia were studied. The diagnosis of chronic B-cell leukemia was based on the morphologic criteria by the latest French-American-British FAB classificationJ and on criteria by National Cancer Institute (NC1)-sponsored CLL working gr0up.2~ Morphologically classical B-CLL was defined when the blood showed lymphocytosis with less than 10% prolymphocytes or large lymphocytes, less than 5% cleaved cells, and 90% or more small lymphocytes. Cases of prolymphocytic leukemia (greater than 55% prolymphocytes) or hairy cell leukemia diagnosed by morphology' were excluded from this study. Cases of the leukemic phase of non-Hodgkin's lymphoma were also excluded from this study. Morphologic classification and Rai stage4 are summarized in Table  1 . The rate of morphologically typical CLL cases with small lymphocytes differs, but not significantly, between CD5+ and CDS-groups (62% v 40%). Other clinical features such as age, sex ratio, and Rai stage were not significantly different between CD5+ and 0 5 -groups.
Immunophenotyping. Peripheral blood samples were obtained after informed consent. Peripheral blood mononuclear cells (PBMC) were separated from heparinized venous blood by density centrifuga- CD5-cases tion using LSM solution (Organon Teknika-Capple, Durham, NC). After being washed with phosphate-buffered saline (PBS) twice, PBMC were then suspended in PBS at the cell density of lo7 cells/ mL. To minimize the nonspecific binding, the PBMC were preincubated in PBS containing 1 mg/mL of immobilized human Ig (Sigma, St Louis, MO) at 4°C for 15 minutes3' or, in the case of staining for surface Ig, in PBS containing 10% normal rabbit serum (Cosmo Bio, Tokyo, Japan) for 30 minutes at 37°C. PBMC were then incubated with two monoclonal antibodies (MoAbs) conjugated with fluorescein isothiocyanate (FITC) and phycoerythrin (PE), respectively, for 20 minutes at 4°C at the concentration recommended by the manufacturer. MoAbs used were Leu-l (CD5), Leu-5 (CD2), Leu-4 (CD3), Leu-3a (CD4), Leu-2a (CD@, Leu-9 (CD7), Leu-12 (CD19). Leu-l6 (CD20). Leu-14 (CD22), Leu-20 (CD23), anti-CALLA (CDlO), anti-IL-2R (CD25), Leu-15 (CDllb), Leu-M7 (CD13), Leu-M9 (CD33), Leu-l8 (CD45RA), MY 7 (CD13), MY 4 (CD14), MY 9 (CD33). MCS-2 (CD13), anti-K Ig, anti-A Ig, antiIgG, anti-IgM, and anti-IgA. MY 7, MY 4, and MY 9 were purchased from Coulter Immunology (Hialeah, FL), MoAbs against IgG, A, and M were purchased from Tag0 (Burlingame, CA), MCS-2 was from Nichirei (Tokyo, Japan), and the other MoAbs and control mouse Igs (IgG 1 and IgG2a) were purchased from Becton-Dickinson (Mountain View, CA). After being washed twice with cold PBS containing 0.1% sodium azide, the stained PBMC (2 X 10" cells per sample) were analyzed using FACScan equipped with Consort 30 software (Becton-Dickinson). The lymphocyte population was gated on a two-parameter forward angle and 90" light scatter cytogram. The percentage of cells expressing the surface antigen of interest was determined by first establishing a cursor position channel using a negative monoclonal control of the same Ig class. The negative control position was set in a channel where 3% or less of the cells were positive for the negative control. To analyze the myelomonocytic antigen (CD1 lb, CD13, CD14, and CD33) expressions on leukemic B cells, dual parameter analyses (combination of Leu-12 and MoAb to myelomonocytic antigen) were performed as shown in Figs 1 and 2. A positive case for any myelomonocytic or restricted B lymphoid (CD10, CD22, and CD23) marker was considered to be expression in 30% or more of the CD19+ cells. The measurement of the mean fluorescence intensity of CD45RA antigen on B cells was performed as previously de~cribed.~' From a dual parameter histogram (combination of FITC-conjugated Leu-l8 and PE-conjugated Leu-12; see Fig 3A) , the CD19+ population (gate (1)) and CD19--CD45RAhigh population (gate (2)) were gated ( Fig 3A) . Mean fluorescence intensities of CD45RA of both gate (1) and gate (2) in each case were calculated using Consort 30 software. Mean fluorescence intensity of CD45RA of the gate (2) population was used as an internal control for each case. The mean fluorescence histogram of the gate (1) population is shown in Fig 3B .
Polymerase chain reaction (PCR) of the expressed V, gene. Total cellular RNA was extracted from PBMC by acid guanidium phenol chloroform methods. 32 Complementary DNA (cDNA) was then synthesized from 3 p g of total cellular RNA using random hexamer primers as previously described.33 One-tenth of the first strand cDNA mixture was amplified by PCR. VH family specific degenerate primers were synthesized based on the leader sequences of Ig VH (Table 2 ) and these were used for 5' primers. Cp 
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CCGAATTCAGACGAGGGGGAAAAGGGTT CY CCGAATTCTAGTCCTTGACCAGGCAGCC primers ( Table 2) were used for 3' primers. PCR amplifications were performed in duplicate from multiple independent first strand cDNA mixtures. Reactions were performed in 50-pL volumes using AmpliTaq Kit (Perkin-Elmer Cetus, Nonvalk, CT) according to the manufacturer's protocol. Amplification consisted of 25 cycles of 1 minute at 93°C 1 minute at 5 7 T , and 1 minute at 72°C (last cycle 10 minutes). PCR-amplified material was fractionated on 1.5% agarose gel containing 1 pg/mL ethidium bromide and visualized by exposure to UV light. Expressed VH family was confirmed by the existence of a DNA band of the expected size (see Fig 5) .
Statistical analysis. x '
Test was used to compare differences in proportions of expression of the surface antigen of interest on leukemic cells between CD5' and CD5-chronic B-cell leukemia cases.
The average fluorescence intensities of CD45RA on B cells among the three groups (CD5' leukemic cases, CD5-cases, and agematched normal volunteers) were compared by Student's t-test. The difference between the observed rate of VH gene family usage to overall use on leukemic cells and the reported rate of germline complexity34 was tested by exactly calculating the total probability of obtaining greater than or equal to the observed frequency, based on binomial distribution" with the number of observations and the reported rate as parameters. Fisher's exact test was used to compare the differences in proportion of expression of the VH gene family use between CD5' and CD5-groups.
RESULTS
Lymphoid marker expression.
The expression of lymphoid surface markers on leukemic cells from 26 Japanese patients is shown in Tables 1 and 3 . Although 15 of 26 patients (58%) had received previous treatment, a high percentage of monoclonal B-cell expansion was shown by the expression of heavy-and light-chain surface Ig restriction. In 2 cases (case no. 8 and case no. lo), although the surface Ig was below the detection level by flow cytometry, PCR of Ig light-chain genes showed only K-chain amplification (data not shown). Of 26 cases, 2 1 (8 1 %) expressed CD5 antigen on leukemic B cells. The expression level of CD5 antigen on CD19+ B cells was lower than that on T cells (data not shown). Other T-cell markers (CD2, CD3, CD4, CD7, CD8) as well as CD10 and CD25 were not expressed on the majority of the leukemic cells (data not shown). CD22 was more frequently expressed in CD5-cases than in CD5+ cases (80% v 33%; P < .05). CD23 expression was observed in 67% of CD5+ cases and in 60% of CD5-cases (Table   3 ). Coexpression of CD22 and CD23 antigens on the leukemic cells was observed in 2 of 21 (10%) CD5+ cases and in 2 of 5 (40%) CD5-cases, respectively.
Myelomonocytic antigen expression. The expression of myelomonocytic surface antigens on leukemic cells is shown in Table 3 . CD13 was expressed on over 30% of CD19+ cells in all CD5-cases examined (5 of 5), whereas CD5' leukemic B cells did not express CD13 antigen, as shown in Fig 1. Three different antibodies against CD13 (Leu M7, MY 7, and MCS-2) show similar reactivity to each case (data not shown). The degree of expression of CD13 antigen varied among the CD5-cases as shown in Table 3 . The majority of leukemic cells from case no. 13, case no. 14, and case no. 23 expressed CD13 antigen, whereas CD13 expression was weak in some of leukemic cells from case no. 5 and case no. 6 by this flow cytometric procedure (Fig  1) . The fluorescence intensities of CD13 on CD5-leukemic B cells were one order or less lower than that expressed on normal granulocytes (data not shown). CDllb was more frequently expressed in CD5-cases than in CD5' cases (80%, 4 of 5 v ]l%, 2 of 18; P < .Ol), as is also shown in Table 3 . The fluorescence intensities of CD1 Ib were not so varied among these positive cases (Fig 2) , but were approximately one order or less lower than that expressed on normal monocytes. The expression of CD14 antigen was observed in only one CD5' case (case no. 10). In this case, CD14 was expressed on approximately 30% of the leukemic cells, as shown in Table 3 . In the present study of 26 cases, CD33 antigen expression on the leukemic cells was not detected 
CD 19 Fig 1. Flow cytometric analysis of cell surface expression of CD13 antigen is shown. Dual-parameter histogram of CD19-FITC (x-axis) and
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in any case using two different MoAbs against CD33 (Leu-
M9 and MY 9).
CD45RA expression. The mean fluorescence intensities of CD45RA antigen on non-B (CD19-)-CD45RAhgh cells (gate (2) population in Fig 3A) were similar in the two groups (CD5' cases, 113.3 2 23.4; CD5-cases, 108.8 5 10.1; mean 5 SD). This indicates that the value does not change among the different samples and is valid as an internal control. The majority of leukemic B cells (gate (1) population in Fig 3A) expressed CD45RA antigen, but the fluorescence intensity of this antigen varied among the cases. The average fluorescence intensity of CD45RA antigen on CD5-leukemic B cells (93.6 5 21.5) was significantly ( P < .01) higher than both that observed on CD5+ leukemic B cells (38.3 +. 28.4) and on age-matched normal volunteers' B lymphocytes (58.6 t 22.0) as shown in Figs 3 and 4 .
V, gene family use.
The frequency of VH gene family use in chronic B-cell leukemias is summarized in Tables 4   and 5 . We performed multiple cDNA synthesis and PCR amplification in each case. Although prepared PBMC contained a vast number of leukemic B cells, the sensitivity of the PCR amplification could potentially result in the amplification of VH gene from contaminating normal B cells. For each case, one or two distinct bands were observed, as exemplified in Fig 5. In some cases, in addition to the major distinct bands, extra faint bands in the PCR using vH3 primers were observed (Fig 5 and Table 4 ). These faint bands were probably derived from contaminating normal B cells. PCR products from 17 cases were cloned, and multiple clones from each case were sequenced. Nucleotide sequences of multiple clones from each case except 1 (case no. 5) displayed identical VH-D-JH recombination that was unique when compared with recombination from other cases (manuscript in preparation). In case no. 5, 6 out of 7 clones displayed identical VH-D-JH recombination. Identical VH-D-JH recombination obtained from independent cDNA/PCR of each case confirmed their clonality and rendered it highly unlikely that they originated from contaminating normal B cells. Of 21 CD5+ cases, 10 (48%) used V& family (Table  5 ). This use of VH4 in CD5+ cases is significantly more frequent (P < .05) than the V& use anticipated by the complexity of the gennline VH fa mil^,^^.^^ whereas CD5-cases used vH3 family members more frequently than CD5+ cases (80% v 24%; P < .05). In this series of cases examined, none of the cases used VH6 family members.
DISCUSSION
The expression of myeloid markers on acute B-cell leukeserved, and its clinical significance has been discussed. However, little is known about the biphenotypic expression in chronic B-cell leukemias. In the present study, we found that two myelomonocytic markers (CD13 and CDllb) are expressed frequently on CD5-leukemic B cells. All of the 
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three different MoAbs against CD13 (MY 7, Leu M7, and MCS-2) reacted with the leukemic cells from all CD5-cases, but none of them reacted with those from CD5+ cases. These findings confirmed CD13 expression on CD5-chronic leukemic B-cells. The positive ratio of CD13+ cases among chronic B-cell leukemia was similar to that reported by Pinto et a137; However, the relationship between CD13 and CD5 antigen expression has not been described. Pinto et a137 reported that CD13 expression on chronic leukemic B cells was associated with unfavorable clinicoprognostic features, such as advanced stage or diffuse bone marrow infiltration. CD13 molecule is a cell surface peptidase (aminopeptidase N) that is able to cleave the N-terminal of amino acid residues from o l i g~p e p t i d e s .~~,~~ This peptidase may modulate growth and differentiation by changing the structure of peptides on the myeloid cell surface.40 There might be some differences in signaling mechanisms concerning the aminopeptidase between CD5'CD13-and CDYCD13' leukemic B cells. These issues and the question as to the existence of a normal B-cell counterpart for CD5-CD13+ phenotype are worth further investigation. Den Ottolander et a141 reported that leukemic cells from 15% of B-CLL cases, but not normal B cells, express CD1 1 b. We observed that leukemic cells from 4 of 5 (80%) CD5-cases express surface CD1 lb, whereas only 2 of 18 (1 1%) of C D 9 cases were positive for CDllb ( P < .01; see Table 3 However, the expression of CD22 was more frequent in leukemic cells from CD5-leukemic cases than in those from CDY cases (80% v 33%; P < .05), whereas the expression of CD23 was similar in both groups (67% v 60%). An inverse relationship between CD23 and CD22 expression was not observed in our study. Although the alternative expression of CD45 isoforms is reported to serve as a marker for functional subsets of T lymphocyte^,^^ little is known about the differential expression of CD45 among B cells. In human B-cell malignancies, the expression level of CD45 and CD45RA increases with maturation stage, and the expression is lost at the stage of plasma~ytoma.~~ The difference in fluorescence intensity of CD45RA between CD5+ and CD5-leukemic B cells may reflect differences in maturation stage between these two leukemic cell populations. Kasaian et a154 recently reported that normal human CDS-CD45RA'""B cells produce polyreactive antibodies and suggested them to be the human counterpart of the murine B-cell sister p o p~l a t i o n .~~ It is unlikely that CD5-chronic B-cell leukemia is derived from this CD5TD45RA'"" normal B-cell subset, because the level of CD45RA expression of CD5-leukemic cells was signifi- cantly higher than that of CDS' leukemic cells or normal B cells.
In the analysis of the VH gene family using PCR method, vH4 family members were found to be used frequently in CDS' chronic B-cell leukemia when compared with the complexity of the VH germline gene reported by Berman et al. 3J and Walter et aL3" The overuse of VH4 gene family members is reported among polyreactive MoAbs generated from CDS' B cells2' and the rheumatoid factors produced by CDS' B cells derived from a rheumatoid arthritis patient.** B cells in human umbilical cord blood are mainly CDS' cells," Table 5 and they use vH4 family members at a high frequency.'6 The preferential use of VF14 gene in CDS' leukemic B cells in the present study may be a reflection of the fetal B-cell repertoire. On the other hand, only few CDS-cases had been examined concerning the V,, gene.5h Herein, we report that CDS-leukemic cells used VH3 family at a high frequency (4 of 5, 80%). These use differences for VH gene family among CDS' and CDS-chronic R-cell leukemias may reflect differences in lineage or ontogeny between CDS' and CDS-leukemic B cells.
In conclusion, we found differences in surface antigen expression between CDS' and CDS-chronic B-cell leuke- almost exclusively in our patient group. Preferential use of V& gene family members were found in CD5' cases, whereas VH3 gene family members were dominant in CD5-cases. These findings would support the hypothesis that CD5-chronic B-cell leukemias may be different from CD5+ cases in origin or differentiation stage. These findings may also support the recent suggestion that CD5 expression in chronic B-cell leukemia is diagnostic for "true" or "typical" CLL.3.9,Lo However, the study scale is limited in our present study in Japan, where the incidence of chronic Bcell leukemia is fairly low. A more generalized and larger study is necessitated to validify these distinctions.
